Vanda Pharmaceuticals Unveils Imsidolimab Data at EADV Meeting

The company’s data highlights the therapeutic potential of imsidolimab, a fully humanized IgG4 monoclonal antibody designed to inhibit IL-36 receptor signaling. Among the findings presented are results from the GEMINI-1 study, which demonstrate the drug’s ability to reduce pustulation as measured by the Pustulation Rating Scale (Abstract ID: AS-2421, Poster P2806).

Additional presentations focus on the physiological impact of the treatment. Researchers detailed a rapid reduction in neutrophils and the neutrophil percentage-to-albumin ratio (Abstract ID: AS-4323, Poster P1769), alongside an assessment of the drug’s immunogenicity (Abstract ID: AS-2420, Poster P1784). Vanda, which holds the exclusive global license for imsidolimab, expects patent and regulatory exclusivity for the orphan drug to remain in effect until the late 2030s.